China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2018 - 2025)

China SXT Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $21.2 million for Q3 2025.

• In Q3 2025, Cash & Equivalents rose 14.33% year-over-year to $21.2 million; the TTM figure through Sep 2025 stood at $21.2 million (up 14.33% YoY), while the FY2025 annual figure was $18.1 million, up 49.95% from the prior year.
• Cash & Equivalents was $21.2 million for Q3 2025 at China SXT Pharmaceuticals, up from $18.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $31.3 billion in Q3 2021 to a low of $3.0 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $3.1 billion across 5 years, with a median of $16.5 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 302416.82% in 2021, then slumped 99.99% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $31.3 billion in 2021, then plunged by 99.99% to $3.0 million in 2022, then soared by 284.6% to $11.5 million in 2023, then soared by 61.47% to $18.5 million in 2024, then gained by 14.33% to $21.2 million in 2025.
• The last three Cash & Equivalents figures came in at $21.2 million (Q3 2025), $18.1 million (Q1 2025), and $18.5 million (Q3 2024), per Business Quant data.